2023 World Conference on Lung Cancer (Posters)-EP01.01. Genomic Alterations of Lung Cancer: Experience in Peru

Pdf Summary

Lung cancer is a leading cause of cancer-related deaths in Peru. However, access to comprehensive molecular profiling, which helps identify genetic alterations for personalized treatment decisions, is limited. This study aimed to describe the mutational landscape of lung cancer patients in Peru to emphasize the need for early access to molecular profiling for improved patient outcomes. <br /><br />The study included 134 lung cancer patients who underwent molecular profiling using various platforms such as PCR, IHC, and NGS. The majority of patients were non-smokers (82.1%). The most frequently tested genes/proteins were PDL1 (10.4%), EGFR (23.1%), and ALK (6.7%). <br /><br />The results showed a high incidence of EGFR alterations, including dual mutations, among lung cancer patients in Peru. Other actionable mutations and co-mutations were also observed. These findings highlight the importance of comprehensive molecular profiling in guiding treatment decisions. <br /><br />The study found that 60.2% of the evaluated patients had at least one actionable target for personalized treatment. <br /><br />Overall, the study emphasizes the need to improve access to comprehensive molecular profiling and targeted therapies for lung cancer patients in Peru. Efforts should be made to increase early access to molecular profiling, as it can significantly improve treatment selection and patient outcomes.

Asset Subtitle

George Oblitas

Meta Tag

Speaker George Oblitas

Topic Risk Factors, Risk Reduction & Tobacco Control

Keywords

lung cancer

Peru

molecular profiling

genetic alterations

personalized treatment

EGFR alterations

actionable mutations

co-mutations

treatment decisions

patient outcomes